Where to invest $10,000 in ASX shares after the market selloff

These shares are highly rated by analysts and could offer major upside.

| More on:
Man holding Australian dollar notes, symbolising dividends.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been a brutal few weeks for the Australian share market.

Trade tensions, rising uncertainty, and a sharp selloff on Wall Street have sent the ASX 200 index tumbling. But while that might be scary for some investors, it is always worth remembering that these are often the moments when long-term wealth is built.

As Warren Buffett once said: "Be fearful when others are greedy and greedy when others are fearful."

And with plenty of fear baked into prices right now, some quality ASX shares are looking better value than they've been in a long time.

If I had $10,000 to invest in the market today, I'd be looking for high-quality businesses that have fallen with the broader market but still have excellent long-term outlooks. And here are three ASX shares that analysts rate as buys that tick that box for me.

ResMed Inc. (ASX: RMD)

ResMed is the global leader in CPAP machines and masks used to treat sleep apnoea, a growing health issue worldwide. The company has delivered consistent sales growth, strong margins, and increasing earnings.

Despite its strength and highly positive outlook, ResMed shares have pulled back materially from their highs during the market selloff. But analysts at Goldman Sachs believe the market has overreacted and see significant value in this ASX share at current levels. The broker currently has conviction buy rating and $49.00 price target on ResMed's shares.

GQG Partners Inc. (ASX: GQG)

This global fund manager might fly under the radar, but it has quietly become one of the most generous dividend payers on the ASX. The company has a history of strong investment performance and has a very favourable dividend policy, which is supported by rising funds under management.

The stock has faced some volatility, but the team at Goldman Sachs remains positive and believes dividend yields above 12% are coming in FY 2025 and FY 2026 based on where its shares trade today. It is partly for this reason that the broker has a buy rating and $3.20 price target on this ASX share.

Temple & Webster Group Ltd (ASX: TPW)

A final ASX share to look at for a $10,000 investment is Temple & Webster. It is one of Australia's leading online homewares and furniture retailers. It has caught the eye of investors in recent years, delivering exceptionally strong sales growth. And with sales in this category still predominantly being made offline, Temple & Webster has a significant growth runway.

Analysts at Citi see major upside ahead for its shares. They recently put a buy rating and $21.10 price target on them.

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in Gqg Partners, ResMed, and Temple & Webster Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, ResMed, and Temple & Webster Group. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Gqg Partners and Temple & Webster Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Broker looking at the share price.
Broker Notes

Broker ratings on 6 ASX shares about to join the ASX 200

These 6 companies will enter the ASX 200 in the December quarter rebalance. Should you buy them?

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Man looking at digital holograms of graphs, charts, and data.
Broker Notes

3 reasons this ASX 300 tech stock is forecast to leap 83% in 2026

A leading broker expects some outsized returns from this ASX 300 tech share. Let’s see why.

Read more »

gold share price represented by speeding golden bullet
Broker Notes

Why this surging ASX All Ords gold stock is tipped to rocket another 233%

A leading broker expects outsized gains from this ASX All Ords gold stock. But not without risk.

Read more »

A blockchain investor sits at his desk with a laptop computer open and a phone checking information from a booklet in a home office setting.
Broker Notes

3 buy-rated ASX 300 shares at 52-week lows

They've fallen far over the past 12 months but have buy ratings from the experts.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Broker Notes

Bell Potter names more of the best ASX 200 shares to buy in December

These are best buys according to the broker. Here's what it is saying about them.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 30% to 40% in 2026

Looking for big returns? Analysts think these shares could beat the market.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Broker Notes

Analysts name 3 ASX shares to buy this week

Analysts have good things to say about these shares.

Read more »